To Evaluate the Response to Glucagon During Hypoglycemia

Completed · Phase 1

Conditions studied: Type 2 Diabetes

In brief

The purpose of this study is to evaluate the response to Glucagon versus the spontaneous hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and Metformin

Key facts

Study ID

NCT00817271

Run by

AstraZeneca

People needed

8

Starts

2009-02-01

Expected to finish

2009-04-01

Last updated by the study team

2009-05-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• type II diabetes patients, female with non child-bearing potential
• T2DM diagnosis confirmed by C-peptide >0.3nmol/L and no glutamic acid decarboxylate (GAD) antibodies at enrolment (screening)
• Treatment with metformin alone with a total daily dose not less than 1 000 mg. Stable glycaemic control indicated by unchanged treatment within 3 months prior to enrolment

You may not qualify if…

• History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
• Signs of diabetic proliferative retinopathy or diabetic maculopathy, at screening or on an ophthalmological examination within 3 months from start of study
• Participating in another clinical study during the last 30 days prior to enrolment

Where it is running

• Research Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.